Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + AK104
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK112 + AK104 is a combination of two bispecific monoclonal antibodies developed for cancer immunotherapy. **AK104** (Cadonilimab/Cardonilizumab) targets both CTLA-4 and PD-1 immune checkpoints, and is approved in China for recurrent/metastatic cervical cancer; it is also in clinical trials for stomach cancer, liver cancer, lung cancer, and ovarian cancer. **AK112** (Ivosi) targets VEGF-A and PD-1 and is in late-stage trials (Phase 3) for non-small cell lung cancer and other solid tumors. The AK112 + AK104 combination is being evaluated, mostly with chemotherapy, for recurrent ovarian cancer and other malignancies in multi-center, open-label Phase 2 studies. Both antibodies re-activate anti-tumor immune responses: AK104 blocks PD-1 and CTLA-4 signaling to stimulate T-cell activity, whereas AK112 blocks PD-1 and VEGF signaling, providing immunomodulation and anti-angiogenic effects[3][4][5][7].
- Brand names
- IvosiCadonilimab
- Other names
- IvosiCadonilimabCardonilizumabKetanyl
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on AK112 + AK104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + AK104.